Statins and cancer prevention
Top Cited Papers
- 1 December 2005
- journal article
- review article
- Published by Springer Nature in Nature Reviews Cancer
- Vol. 5 (12) , 930-942
- https://doi.org/10.1038/nrc1751
Abstract
Randomized controlled trials for preventing cardiovascular disease indicated that statins had provocative and unexpected benefits for reducing colorectal cancer and melanoma. These findings have led to the intensive study of statins in cancer prevention, including recent, large population-based studies showing statin-associated reductions in overall, colorectal and prostate cancer. Understanding the complex cellular effects (for example, on angiogenesis and inflammation) and the underlying molecular mechanisms of statins (for example, 3-hydroxy-3-methylglutaryl coenzyme-A (HMG-CoA) reductase-dependent processes that involve geranylgeranylation of Rho proteins, and HMG-CoA-independent processes that involve lymphocyte-function-associated antigen 1) will advance the development of molecularly targeted agents for preventing cancer. This understanding might also help the development of drugs for other ageing-related diseases with interrelated molecular pathways.Keywords
This publication has 112 references indexed in Scilit:
- PLEIOTROPIC EFFECTS OF STATINSAnnual Review of Pharmacology and Toxicology, 2005
- Geranylgeranylated, but not farnesylated, RhoB suppresses Ras transformation of NIH-3T3 cellsExperimental Cell Research, 2005
- Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma PreventionNew England Journal of Medicine, 2005
- Anti-RhoA and Anti-RhoC siRNAs Inhibit the Proliferation and Invasiveness of MDA-MB-231 Breast Cancer Cells in Vitro and in VivoMolecular Therapy, 2005
- Functional Analysis of the Contribution of RhoA and RhoC GTPases to Invasive Breast CarcinomaCancer Research, 2004
- Depletion of membrane cholesterol causes ligand-independent activation of Fas and apoptosisPublished by Elsevier ,2004
- Isoprenylation is Necessary for the Full Invasive Potential of RhoA Overexpression in Human Melanoma CellsJournal of Investigative Dermatology, 2002
- The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune diseaseNature, 2002
- HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosisLeukemia, 2002
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998